GeneDx Investors Face August Deadline in Securities Class Action

Investors who purchased GeneDx Holdings Corp. common stock between April 16, 2025, and May 4, 2026, have until August 3, 2026, to seek lead plaintiff status in a newly filed securities fraud class action lawsuit currently pending in the U.S. District Court for the District of Connecticut.

Corp and Tech·July 18, 2026·reads: 879

The litigation, titled Taher Basma v. GeneDx Holdings Corp., centers on the company’s acquisition of Fabric Genomics. When GeneDx announced the deal in April 2025, it touted the acquisition as a move to expand its addressable market through scalable revenue streams and AI-driven genomic interpretation software. However, the lawsuit alleges that the company misrepresented the financial viability of Fabric Genomics, effectively misleading investors about the company's true operational prospects.

The alleged deception came to light on May 4, 2026, when GeneDx reported its first-quarter results. The company revealed lowered earnings projections and disappointing reimbursement rates, alongside a $31.3 million impairment loss tied directly to the Fabric acquisition—a figure nearly equivalent to the initial $33 million cash outlay for the firm. Following this disclosure, GeneDx shares plummeted by more than 49%.

Kessler Topaz Meltzer & Check, LLP is currently evaluating claims for affected investors. Those interested in serving as lead plaintiff must file their motions with the court by the August 3 deadline. Participation in the litigation is voluntary, and investors may choose to remain absent class members or retain their own counsel.